Provided is a cancer therapeutic agent comprising a cancer targeting moleculelinked to a liver-expressed chemokine (LEC). In one embodiment, the cancertargeting molecule is an antibody that targets cancer cells or tumors in vivo.The cancer targeting molecule is associated non-covalently or covalently withLEC. The cancer therapeutic agents of the invention are useful for thetreatment of cancer in an individual by reducing the size of a tumor orinhibiting the growth of cancer cells in an individual and/or by inhibitingthe development of metastasis. The effectiveness of the therapy using the LECcancer therapeutic agents can be increased by reducing the activity ofimmunoregulatory T cells and/or by adoptively transferring immune T cells.
